<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404558</url>
  </required_header>
  <id_info>
    <org_study_id>PDY14191</org_study_id>
    <secondary_id>U1111-1163-1359</secondary_id>
    <nct_id>NCT02404558</nct_id>
  </id_info>
  <brief_title>Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>An Open-label, Randomized, Parallel Group, Single-dose Study to Describe the Safety of IL-6 Receptor Blockade With Sarilumab or Tocilizumab Monotherapy in Japanese Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To describe the safety and tolerability, including laboratory abnormalities following a
      single dose of sarilumab or tocilizumab administered subcutaneously (SC) as monotherapy in
      Japanese patients with rheumatoid arthritis (RA).

      Secondary Objectives:

      To describe the laboratory abnormalities (absolute neutrophil count [ANC], platelet counts,
      total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL]
      cholesterol, and liver function tests [LFTs]) following a single dose of sarilumab or
      tocilizumab administered SC as monotherapy in Japanese patients with RA.

      To describe the pharmacokinetics (PK) of sarilumab and tocilizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total study duration (per patient) is expected to be up to 71 days including screening (3 to
      28 days before dosing).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with potentially clinically significant laboratory abnormalities</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in laboratory parameters (hematology and biochemistry)</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weighted average of change from baseline in laboratory parameters (hematology and biochemistry)</measure>
    <time_frame>Baseline, Day 15</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: maximum concentration (Cmax)</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: time to Cmax (tmax)</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter: area under the curve from zero time until the last measurable concentration (AUClast)</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in laboratory parameters (hematology and biochemistry)</measure>
    <time_frame>Baseline, Day 29 and Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted average of change from baseline in laboratory parameters (hematology and biochemistry)</measure>
    <time_frame>Baseline, Day 29 and Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Sarilumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous (SC) dose of sarilumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single SC dose of tocilizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sarilumab SAR153191 (REGN88)</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: Subcutaneous injection</description>
    <arm_group_label>Sarilumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tocilizumab</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: Subcutaneous injection</description>
    <arm_group_label>Tocilizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients with rheumatoid arthritis (RA) as defined by the American College of
             Rheumatology (ACR)/European League against Rheumatism (EULAR) 2010

          -  Rheumatoid Arthritis Classification Criteria.

          -  ACR Class I-III functional status, based on the 1991 revised criteria.

        Exclusion criteria:

          -  Patients less than 20 years of age.

          -  Prior treatment with any biologic anti-interleukin-6 (anti-IL-6) or interleukin-6
             receptor (IL-6R) antagonist.

          -  Any parenteral or intraarticular glucocorticoid injection within 4 weeks prior to
             randomization.

          -  Treatment with prednisone higher than 10 mg or equivalent per day, or change in dosage
             within 4 weeks prior to randomization.

          -  Treatment with disease-modifying antirheumatic drugs (DMARDs), immunosuppressive
             agents, tumor necrosis factor (TNF) antagonists or any other RA-directed biologic
             agents within a certain amount of time prior to randomization.

          -  Participation in any clinical research study that evaluated an investigational drug or
             therapy within 5 half-lives or 60 days of the screening visit, whichever is longer.

          -  Active or suspected tuberculosis (TB) or at high risk of contracting TB.

          -  Fever, or chronic, persistent, or recurring infection(s) requiring active treatment.

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392001</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392002</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392003</name>
      <address>
        <city>Sendai-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2015</study_first_submitted>
  <study_first_submitted_qc>March 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

